AmpliPhi Biosciences Corporation [APHB.PK], created in 2011 through the merger of Biocontrol Limited with Targeted Genetics Inc., and subsequent combination with Special Phage Services in 2012, is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human and animal health through the application of its proprietary bacteriophage platform. The Company’s lead product development programs are targeting Gram-negative infections that are often resistant to existing antibiotic treatments.

Based in Richmond, Virginia, USA with additional facilities in the Colworth, UK and Sydney, Australia.